Drilldown: Medicines

Other values:

Search

None (86) · Delysid (historical, Sandoz, withdrawn 1965) (1) · DXM (1) · DXO (1) · Spravato (1) · Trulicity (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · NMDA antagonist (3) · Contains LSA (2) · Contains mescaline (2) · NMDA antagonist; sigma receptor agonist (2)

Other values:

Search

None (89) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) · [[Type 2 diabetes mellitus]] · [[Cardiovascular risk reduction]] in T2DM (1)

None (89) · 0.75 mg SC weekly'"`UNIQ--ref-00000053-QINU`"' (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

None (89) · 28 mg/device (each dose uses 2 devices) (1) · Pre-filled single-dose pen: 0.75 / 1.5 / 3 / 4.5 mg'"`UNIQ--ref-00000054-QINU`"' (1)

None (89) · 4.5 mg/wk SC'"`UNIQ--ref-00000055-QINU`"' (1) · 84 mg per session (1)

None (88) · Intranasal (under direct medical supervision) (1) · Oral (1) · Subcutaneous (abdomen (1) · thigh (1) · upper arm)'"`UNIQ--ref-00000056-QINU`"' (1)

None (88) · 30–60 minutes (1) · Glycemic effect within days; near-maximal HbA1c effect by 4 weeks at any given dose'"`UNIQ--ref-00000057-QINU`"' (1) · Within hours of first administration (1)

None (88) · 8–12 hours (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · ~7 days (weekly dosing)'"`UNIQ--ref-00000058-QINU`"' (1)

None (88) · 3–5 hours (1) · ~5 days (~120 h)'"`UNIQ--ref-00000059-QINU`"' (1) · ~7-12 hours (1)

None (88) · 70–90% (oral) (1) · SC ~47%–65%'"`UNIQ--ref-0000005A-QINU`"' (1) · ~48% intranasal (1)

None (88) · Avoid. Discontinue at least 1 month before planned pregnancy. Animal data show embryofetal harm.'"`UNIQ--ref-0000005B-QINU`"' (1) · Avoid; may cause fetal harm (1) · Not established (1)

None (88) · Rx, Schedule III (US). REMS program required. (1) · Rx-only;'"`UNIQ--ref-0000005C-QINU`"' not a controlled substance (1) · Schedule I (United States) (1)